Specialty: Respiratory disorders, Primary sub-specialty: Respiratory disorders
Conditions
Interventions
My Breathing Matters is a digital intervention for the self-management of asthma, consisting of pharmacological support, (advice about asthma reviews and personal asthma action plans, information abou
Sponsors
University of Southampton
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 18 years and over 2. Physician diagnosed asthma in medical record 3. At least one anti-asthma medication prescription in the previous year (determined from the physician prescribing records) 4. Impaired asthma-related health status (Asthma Quality of Life Questionnaire score of <5.5) 5. Informed consent 6. Able to access the internet and understand written English
Exclusion criteria
Exclusion criteria: 1. Asthma judged at the baseline assessment to be dangerously unstable and in need of urgent medical review (if unstable asthma is found, the patient will be referred back to usual primary care clinician for review) 2. Terminal disease or other condition which in the opinion of the family doctor makes them inappropriate to take part 3. Diagnosed with ‘difficult asthma’ as defined by BTS 4. Documented diagnosis of Chronic Obstructive Pulmonary Disease (COPD) 5. Household member already enrolled on the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility and acceptability of intervention and trial procedures, including: 1. Uptake assessed using data from recruitment and data collection procedures 2. Adherence assessed throughout the study using data from questionnaire response rates 3. Completion rates measured using data from questionnaire and interview response rates | — |
Secondary
| Measure | Time frame |
|---|---|
| Feasibility of measuring (and estimates of effect size to perform sample size calculations) in the following trial measures: 1. Asthma-specific quality of life assessed using the AQLQ questionnaire - short version at baseline, 3 months and 12 months 2. Asthma control assessed using the Asthma Control Questionnaire (ACQ) at baseline, 3 months and 12 months 3. Lung function assessed using standard tests (FEV1, FEV1/FVC, PEFR) at baseline, 3 months and 12 months 4. Quality of life and wellbeing assessed using the EQ5D and ICECAP-A questionnaires at baseline, 3 months and 12 months 5. Anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS) at baseline, 3 months and 12 months 6. Patient enablement assessed using the Patient Enablement Instrument (PEI) at baseline, 3 months and 12 months 7. Patient burden (time and costs) measured using the Southampton Time & Costs Measure at 12 months 8. Health resource use (professional contacts, referrals, prescriptions) assessed using notes review at 12 months 9. Adherence to recommendations assessed using notes review at 12 months 10. Medication adherence using Medication Adherence Report Scale for Asthma (MARS-A) questionnaire at baseline, 3 months and 12 months | — |
Countries
England, United Kingdom
Contacts
Public ContactVictoria Hayter
Outcome results
None listed